Exondys 51

Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug

Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics

Sarepta's Beat And Raise Streak Continues

Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics

Sarepta's Beat And Raise Streak Continues

Sarepta's Upside Story Is Just Getting Started

U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'

Sarepta's Upside Story Is Just Getting Started

U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'

Sarepta Marks A 'Very Important Day' For The DMD Community

Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?

Exondys 51 Recent News

Exclusive: Capricor CEO Talks Exondys Competition

Here's Why Sarepta Therapeutics May Be The Rarest Of Finds: A 'Value' Biotech Stock

Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys

The Street Is Misreading Sarepta's Guidance

Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results

FDA 101: What Does 'Orphan Drug Designation' Mean?

For Sapreta, Today's Good News Might Be Just The Beginning

Sarepta Soars Following Encouraging Exondys 51 News

Credit Suisse Says Sarepta Shares Volatile, Still A Favorite Idea

2016's Most Hyped Events: How Did It Work Out For The Stocks?

The Rise And Fall Of Sarepta's Stock Since Exondys 51 Accelerated Approval

Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage

New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51

Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment

3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'

For Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform

Sarepta Shares Continue Rally As Analysts Flip To Positive

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform